Advertisement
Screener

Indivior Pharmaceuticals, Inc. (INDV) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Indivior Pharmaceuticals, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2026-06-30 was -169.05%, a change of -127.35% year-over-year.
  • Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2026-03-31 was -171.92%, a 7148.63% decline year-over-year.
  • Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2025-12-31 was -209.00%, a change of -206.94% year-over-year.
  • Indivior Pharmaceuticals, Inc. return tang equity for the quarter ending 2025-09-30 was -61.24%.
  • Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2025 was -210.00%, a change of -207.94% from fiscal 2024.
  • Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2024 was -2.06%, a 103.10% decline from fiscal 2023.
  • Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2023 was 66.67%, a 77.27% decline from fiscal 2022.
  • Indivior Pharmaceuticals, Inc. return tang equity for fiscal 2022 was 293.33%.
Available history
2022-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-169.05%$355M-$210M
2026-03-31-171.92%$251M-$146M
2025-12-31-209.00%$209M-$100M
2025-09-30-61.24%$128M-$209M
2025-06-30-41.70%$108M-$259M
2025-03-312.44%-$7M-$287M
2024-12-31-2.06%$7M-$339M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-210.00%$210M-$100M
2024-12-31-2.06%$7M-$339M
2023-12-3166.67%-$126M-$189M
2022-12-31293.33%-$44M-$15M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Veradermics, Inc (MANE)United States$4.839B
Organon & Co. (OGN)United States$3.603B17.03
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Erasca, Inc. (ERAS)United States$5.073B-19.96